

UK NEQAS FOR H&I SCHEME 2B - CROSSMATCHING BY FLOW CYTOMETRY

T-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B04/2014 (COMPARED TO LOCAL NEGATIVE CONTROL)

DESPATCHED ON 11TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A24, A29; B42, B44; Cw16, Cw17; DR7, DR13; DQ2, DQ7

Summary of Results

| | | | | |
|--------------|-------|-------|--------|-------|
| Total tested | 46 | 43 | 46 | 46 |
| Positive | 2 | 19 | 0 | 3 |
| Negative | 44 | 24 | 46 | 43 |
| Not Tested | 2 | 2 | 2 | 2 |
| % Positive | 4.3% | 44.2% | 0.0% | 6.5% |
| % Negative | 95.7% | 55.8% | 100.0% | 93.5% |

| | | | | |
|----------------------------------|-----------------|---------------------|-----------------|-----------------|
| Consensus | Negative | Not Assessed | Negative | Negative |
| HLA Antibody (Defined By CDC) | B57 | A2, A28 | B8 | B12 |

| Lab No. | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Date Received | Date Tested | Comments |
|---------|----------|---------------|----------|---------------|---------------|-------------|---|
| 112 | Negative | Positive | Negative | Negative | 14-Mar | 14-Mar | |
| 114 | Negative | Negative | Negative | Negative | 13-Mar | 14-Mar | |
| 115 | Negative | Negative | Negative | Negative | 12-Mar | 13-Mar | |
| 116 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 117 | Negative | Equivocal | Negative | Negative | 13-Mar | 13-Mar | |
| 118 | Negative | Positive | Negative | Negative | 11-Mar | 11-Mar | |
| 119 | Negative | Weak Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 120 | Negative | Negative | Negative | Negative | 12-Mar | 13-Mar | T-cell: Ratio/Tem- <1.6 (-) |
| 122 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 126 | Negative | Negative | Negative | Negative | 11-Mar | 11-Mar | |
| 130 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 136 | Negative | Negative | Negative | Negative | 13-Mar | 14-Mar | |
| 138 | Negative | Negative | Negative | Negative | 13-Mar | 13-Mar | |
| 142 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 143 | NT | NT | NT | NT | 13-Mar | 14-Mar | Technical error |
| 144 | Negative | Negative | Negative | Negative | 13-Mar | 14-Mar | |
| 145 | Negative | Positive | Negative | Negative | 14-Mar | 14-Mar | |
| 147 | Negative | Negative | Negative | Negative | 12-Mar | 12-Mar | |
| 154 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 157 | Negative | Negative | Negative | Negative | 12-Mar | 12-Mar | |
| 159 | Negative | Negative | Negative | Negative | 13-Mar | 13-Mar | |
| 160 | Negative | Negative | Negative | Positive | 12-Mar | 13-Mar | |
| 163 | Negative | Weak Positive | Negative | Negative | 12-Mar | 12-Mar | |
| 164 | Negative | Negative | Negative | Negative | 12-Mar | 13-Mar | |
| 167 | Negative | Positive | Negative | Weak Positive | 12-Mar | 13-Mar | |
| 169 | Negative | Negative | Negative | Negative | 14-Mar | 14-Mar | |
| 176 | Negative | Negative | Negative | Negative | 13-Mar | 14-Mar | |
| 186 | Negative | Equivocal | Negative | Negative | 12-Mar | 12-Mar | |
| 190 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 191 | Positive | Negative | Negative | Negative | 12-Mar | 13-Mar | |
| 193 | Negative | Positive | Negative | Negative | 12-Mar | 12-Mar | |
| 194 | Negative | Negative | Negative | Negative | 12-Mar | 12-Mar | |
| 195 | Negative | Negative | Negative | Negative | 14-Mar | 14-Mar | |
| 201 | Negative | Negative | Negative | Negative | 12-Mar | 13-Mar | |
| 202 | Negative | Negative | Negative | Negative | 13-Mar | 13-Mar | |
| 204 | Negative | Negative | Negative | Negative | 12-Mar | 12-Mar | |
| 209 | Negative | Negative | Negative | Negative | 12-Mar | 13-Mar | |
| 218 | Positive | Positive | Negative | Positive | 12-Mar | 14-Mar | Serum 3 was borderline on the cut-off used, but was negative in comparison to the other negative controls |
| 220 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 227 | NT | NT | NT | NT | | | |
| 235 | Negative | Negative | Negative | Negative | 12-Mar | 12-Mar | |
| 238 | Negative | Equivocal | Negative | Negative | 12-Mar | 13-Mar | |
| 245 | Negative | Weak Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 246 | Negative | Positive | Negative | Negative | 12-Mar | 12-Mar | |
| 252 | Negative | Negative | Negative | Negative | 13-Mar | 13-Mar | |
| 262 | Negative | Negative | Negative | Negative | 13-Mar | 13-Mar | |
| 271 | Negative | Positive | Negative | Negative | 16-Mar | 17-Mar | |
| 283 | Negative | Positive | Negative | Negative | 12-Mar | 12-Mar | |

UK NEQAS FOR H&I SCHEME 2B - CROSSMATCHING BY FLOW CYTOMETRY

T-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B04/2014 (COMPARED TO LOCAL NEGATIVE CONTROL)

DESPATCHED ON 11TH MARCH 2014

| Lab No. | Serum 1 cytometer reading | Serum 2 cytometer reading | Serum 3 cytometer reading | Serum 4 cytometer reading | Negative control (local) | Positive control (local) | Strong positive (local) | Weak positive (local) | Positive result value | Cytometer reading units | FCXM NIBSC negative control used? |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|--------------------------|--------------------------|-------------------------|-----------------------|--|-------------------------------|-----------------------------------|
| 112 | 0.324 | 1.34 | 0.312 | 0.424 | 0.341 | 1.51 | | | >1.5 ratio | Median log channel | No |
| 114 | 233 | 250 | 223 | 224 | 234 | 426 | | | 284 (234+50) | Median linear channel | No |
| 115 | 184 | 224 | 174 | 196 | 186 | 326 | | | >40 channel shift | Median linear channel shifts | Yes |
| 116 | 0.23 | 0.48 | 0.19 | 0.26 | 0.17 | 24360 | | | Ratio >1.7 | Median log channel | No |
| 117 | 3.78 | | 3.61 | 3.84 | 3.6 | 78.22 | | | Ratio (RMF) >1.3 | Median log channel | Yes |
| 118 | 188 | 205 | 172 | 177 | 175 | 811 | | | 197 (175+22) | Median linear channel | Yes |
| 119 | 0.242 | 0.527 | 0.244 | 0.253 | 0.226 | 3.9 | | | T-XM: Ratio >1.285 B-line [-1.48] | MuX | No |
| 120 | 99 | 130 | 96 | 104 | 92 | 8612 | | | Neg control median x1.6 | Median | No |
| 122 | 7 | 10.5 | 6 | 7 | 6 | | 24 | 10 | 3SD | Geomean linear values | Yes |
| 126 | 129 | 166 | 110.5 | 138 | 117 | 604 | | | >55 | Median linear shift | No |
| 130 | 145 | 187 | 147 | 160 | 144 | 259 | | | >40 | | No |
| 136 | 2 | 2.4 | 1.7 | 2.9 | 1.7 | 36 | | | NR >200 | Mean channel | No |
| 138 | 0.09 | 0.03 | 0.12 | 0.05 | 0 | 0.94 | | | NR=2038 | | |
| 142 | 86 | 224 | 83 | 67 | 91 | 5596 | | | >0.20 | Kolmogorov-Smirnov (D value) | No |
| 143 | NT | NT | NT | NT | NT | | NT | NT | 109.73, 3SD | Median log channel | No |
| 144 | MFI 8.15 | 11.16 | 7.6 | 9.36 | 7.85 | 66.19 | | | ≥40 | NT | No |
| 145 | Ratio 1.04 | 1.42 | 0.97 | 1.19 | 1 | 8.43 | | | 1.76 | | No |
| 147 | 0.199 | 0.236 | 0.176 | 0.192 | 0.171 | 61.9 | | | Med log ch test/Med log ch neg >mean +2SD | Median log channel | No |
| 154 | 97 | 110 | 92 | 95 | 97 | 448 | | | >60 linear channel shift | Median linear channel | No |
| 157 | 1.67 | 2.73 | 1.67 | 1.81 | 1.66 | 38.28 | | | GMFI >115% control x shape of the curve | GMFI | No |
| 159 | 96 | 101.5 | 102.5 | 102 | 100.5 | 371.5 | | | 125.5 (Neg +25) | Median linear channel | No |
| 160 | 171 | 202 | 160 | 167 | 165 | 328 | | | 205 (40 mean linear channel shift) | Mean linear channel | No |
| 163 | 8.1 | 11.7 | 7.4 | 67.4 | 7.3 | 210 | | | >14.1 (Neg +2SD) | Mean linear channel | No |
| 164 | 1.3 | 2.6 | 1 | 1.6 | 1 | 5.8 | | | 2.3 Geomean log channel | Geomean log channel | Yes |
| 166 | 3 | 4.5 | 2 | 3.5 | 2 | 105 | | | 6 (3x MFI neg control) | MFI | No |
| 167 | 6 | 10 | 6 | 8 | 5 | 478 | | | 2SD | Median log channel | No |
| 169 | MLC 6.10 | 5.7 | 5.41 | 5.39 | 7.06 | 881.01 | | | | | |
| 176 | NR 86 | 80 | 77 | 76 | | 12479 | | | NR= (MFI serum/MFI neg control) x100 Positive= NR >180 T-cell SI≥0.5 | Mean log channel | No |
| 186 | SI .09 | 0.3 | -0.08 | 0.26 | 0 | 1.77 | | | | | No |
| 190 | MESF 1.306 | 1.964 | 890 | 1.794 | 1.071 | 21.912 | | | | | No |
| 191 | 0.285 | 0.355 | 0.271 | 0.287 | 0.3 | 15.3 | | | 1.5 fold of local negative | MFI log channel | No |
| 193 | 41.2 | 52.5 | 39.6 | 41.35 | 39.17 | 73.5 | | | Ratio Sample/Negative >1.2 | Mean linear channel | No |
| 199 | MFI 8 | 2 | -1.5 | -1.2 | | 298 | | | MFI >5 | | No |
| 201 | 1.5% | 0.95% | 0.66% | 0.76% | | 96% | | | >5% | | No |
| 203 | 3.17 | 7.85 | 2.79 | 3.77 | 2.39 | 329.2 | | | Negative control mean x2.5 | Geometric mean linear channel | No |
| 204 | 0.102 | 0.103 | 0.11 | 0.11 | 0.108 | 2 | | | Ratio >1.5 | MuX | No |
| 205 | 275 | 320 | 254 | 290 | 259 | 3481 | | | Test/Neg control >1.25 | Median log channel | Yes |
| 206 | 0.28 | 0.36 | 0.27 | 0.28 | 0.27 | 9.55 | | | x-mean ratio ≥2 | x-mean | No |
| 207 | 1 | 1 | 1 | 2 | 2 | 99 | | | 5% above the local negative control | Linear | No |
| 208 | 0.31 | 0.4 | 0.3 | 0.3 | 0.31 | 10.3 | | | 0.48 = 1.5x local neg control | Mean log channel | No |
| 209 | 1.18 | 1.52 | 1 | 1.12 | 254 | 660 | | | >1.63 ratio | Geomean log channel | Yes |
| 210 | 172 | 322 | 114 | 175 | 93.8 | 4174 | | | 93.8 x1.2 = 112.56 | Geometric MFI | No |
| 211 | 7.38 | 8.67 | 7.65 | 7.6 | 7.46 | | 177.77 | 24.95 | 2SD | | No |
| 212 | | | | | | | | | | | |
| 213 | 1.1 | 0.91 | 0.76 | 0.76 | 0.91 | 18.6 | | | Median +2SD | Median log channel | No |
| 214 | 623 | 816 | 525 | 608 | 599 | 5658 | | | MESF serum/MESF neg control | MESF | No |
| 215 | 1.2 | 6.2 | 0.7 | 1.7 | 6.3 | 18.5 | | | 7 linear channel shift | Linear channel shift | Yes |
| 216 | <1% | 57.3% | <1% | <1% | <1% | 91% | | | 30% | | No |
| 217 | 0.95 | 0.96 | 0.93 | 0.98 | | | | | xm median channel/neg median channel | Median channel ratio | No |
| 218 | | | | | 1242 | 27827 | | | Sample/Neg >2 | Median channel log | No |
| 219 | | | | | | | | | Cell lysis >12% | | |
| 220 | 140 | 254 | 131 | 175 | 169 | 325 | | | 67 log channel shift | Median log channel | No |
| 221 | -15 | 23.45 | -26.57 | 8.64 | 32.78 | 54.6 | | | 20 channel shift | Channel shift | No |

UK NEQAS FOR H&I SCHEME 2B - CROSSMATCHING BY FLOW CYTOMETRY

B-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B04/2014 (COMPARED TO LOCAL NEGATIVE CONTROL)

DESPATCHED ON 11TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A24, A29; B42, B44; Cw16, Cw17; DR7, DR13; DQ2, DQ7

Summary of Results

| | | | | |
|--------------|-------|-------|-------|-------|
| Total tested | 43 | 44 | 40 | 44 |
| Positive | 24 | 43 | 20 | 2 |
| Negative | 19 | 1 | 20 | 42 |
| Not Tested | 1 | 1 | 2 | 1 |
| % Positive | 55.8% | 97.7% | 50.0% | 4.5% |
| % Negative | 44.2% | 2.3% | 50.0% | 95.5% |

| Consensus | Not Assessed | Positive | Not Assessed | Negative |
|----------------------------------|--------------|----------|--------------|----------|
| HLA Antibody (Defined By CDC) | B57 | A2, A28 | B8 | B12 |

| Lab No. | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Date Received | Date Tested | Comments |
|---------|---------------|----------|---------------|----------|---------------|-------------|--|
| 112 | Positive | Positive | Positive | Negative | 14-Mar | 14-Mar | |
| 114 | Negative | Positive | Negative | Negative | 13-Mar | 14-Mar | |
| 115 | Negative | Positive | Positive | Negative | 12-Mar | 13-Mar | |
| 116 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 117 | Positive | Positive | Positive | Negative | 13-Mar | 13-Mar | |
| 118 | Negative | Positive | Negative | Negative | 11-Mar | 11-Mar | |
| 119 | Positive | Positive | Positive | Negative | 12-Mar | 13-Mar | |
| 120 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | B-cell: Ratio/Tem- <2 (-) |
| 122 | Positive | Positive | Positive | Positive | 12-Mar | 13-Mar | |
| 126 | Positive | Positive | NT | Negative | 11-Mar | 11-Mar | Serum 3 - Technical problem |
| 130 | Positive | Positive | Positive | Negative | 12-Mar | 13-Mar | |
| 142 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 144 | Negative | Positive | Negative | Negative | 13-Mar | 14-Mar | |
| 145 | Negative | Positive | Negative | Negative | 14-Mar | 14-Mar | |
| 147 | Positive | Positive | Positive | Negative | 12-Mar | 12-Mar | |
| 154 | Positive | Positive | Positive | Negative | 12-Mar | 13-Mar | |
| 157 | Negative | Positive | Negative | Negative | 12-Mar | 12-Mar | |
| 159 | Positive | Positive | Positive | Negative | 13-Mar | 13-Mar | |
| 160 | Positive | Positive | Weak Positive | Negative | 12-Mar | 13-Mar | |
| 163 | Negative | Positive | Negative | Negative | 12-Mar | 12-Mar | |
| 164 | Positive | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 167 | Negative | Positive | Positive | Negative | 12-Mar | 13-Mar | |
| 169 | Negative | Negative | Negative | Negative | 14-Mar | 14-Mar | |
| 176 | Negative | Positive | Negative | Negative | 13-Mar | 14-Mar | |
| 186 | Negative | Positive | Negative | Negative | 12-Mar | 12-Mar | |
| 190 | Positive | Positive | Positive | Negative | 12-Mar | 13-Mar | |
| 191 | Positive | Positive | Positive | Negative | 12-Mar | 13-Mar | |
| 193 | Equivocal | Positive | Equivocal | Negative | 12-Mar | 12-Mar | |
| 194 | Positive | Positive | Positive | Negative | 12-Mar | 12-Mar | |
| 195 | Positive | Positive | Positive | Negative | 14-Mar | 14-Mar | |
| 201 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 202 | Negative | Positive | Negative | Negative | 13-Mar | 13-Mar | |
| 204 | Negative | Positive | Negative | Negative | 12-Mar | 12-Mar | |
| 209 | Positive | Positive | Positive | Negative | 12-Mar | 13-Mar | |
| 218 | Positive | Positive | Negative | Negative | 12-Mar | 14-Mar | Serum 2 had very few B-cells which may have skewed the results |
| 220 | Negative | Positive | Negative | Negative | 12-Mar | 13-Mar | |
| 227 | NT | NT | NT | NT | | | |
| 235 | Positive | Positive | Negative | Negative | 12-Mar | 12-Mar | |
| 238 | Positive | Positive | Equivocal | Negative | 12-Mar | 13-Mar | |
| 245 | Positive | Positive | Weak Positive | Negative | 12-Mar | 13-Mar | |
| 246 | Positive | Positive | Positive | Negative | 12-Mar | 12-Mar | |
| 252 | Positive | Positive | Positive | Positive | 13-Mar | 13-Mar | |
| 262 | Weak Positive | Positive | Equivocal | Negative | 13-Mar | 13-Mar | |
| 271 | Positive | Positive | Positive | Negative | 16-Mar | 17-Mar | |
| 283 | Negative | Positive | Negative | Negative | 12-Mar | 12-Mar | |

UK NEQAS FOR H&I SCHEME 2B - CROSSMATCHING BY FLOW CYTOMETRY

B-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B04/2014 (COMPARED TO LOCAL NEGATIVE CONTROL)

DESPATCHED ON 11TH MARCH 2014

| Lab No. | Serum 1 cytometer reading | Serum 2 cytometer reading | Serum 3 cytometer reading | Serum 4 cytometer reading | Negative control (local) | Positive control (local) | Strong positive (local) | Weak positive (local) | Positive result value | Cytometer reading units | FCXM NIBSC negative control used? |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|--------------------------|--------------------------|-------------------------|-----------------------|---|-------------------------------|-----------------------------------|
| 112 | 2.28 | 70.2 | 3.61 | 0.871 | 0.554 | 29.1 | | | >2.0 ratio | Median log channel | No |
| 114 | 443 | 512 | 427 | 395 | 430 | 687 | | | 490 (430+60) | Median linear channel | No |
| 115 | 428 | 669 | 490 | 414 | 382 | 502 | | | >100 channel shift | Median linear channel shifts | Yes |
| 116 | 6.25 | 25.8 | 3.33 | 4.64 | 6.8 | 56.4 | | | Ratio >1.7 | Median log channel | No |
| 117 | 27.75 | 150.22 | 39.37 | 12.81 | 9.61 | 252.74 | | | Ratio (RMF) >1.5 | Median log channel | Yes |
| 118 | 148 | 285 | 155 | 147 | 147 | 537 | | | 173 (147+26) | Median linear channel | Yes |
| 119 | 11.2 | 34.2 | 8.98 | 4.14 | 2.28 | 13.5 | | | B-XM: Ratio >1.7 B-line [1.5-1.7] | MuIX | No |
| 120 | 1083 | 7063 | 1105 | 618 | 601 | 18869 | | | Neg control median x2 | Median | No |
| 122 | 86.5 | 540.5 | 75 | 60.5 | 27 | | 153 | 55 | 3SD | Geomean linear values | Yes |
| 126 | 361.5 | 612.5 | NT | 251.5 | 233 | 760 | | | >80 | Median linear shift | No |
| 130 | 434 | 653 | 420 | 340 | 327 | 453 | | | >80 | | No |
| 142 | 715 | 5977 | 735 | 792 | 790.67 | 17901 | | | 984.91, 3SD | Median log channel | No |
| 144 | MFI 68.37 Ratio 1.92 | 341.53 9.59 | 64.73 1.82 | 52.12 1.46 | 35.6 1 | 264.21 7.42 | | | 3 | | No |
| 145 | 1.13 | 6.51 | 1.07 | 0.659 | 0.887 | 104 | | | Med log ch test/Med log ch neg >mean +2SD | Median log channel | No |
| 147 | 277 | 489 | 279 | 171 | 178 | 598 | | | >60 linear channel shift | Median linear channel | No |
| 154 | 14.7 | 145.75 | 18.26 | 10.83 | 9.53 | 189.91 | | | GMFI >115% control x shape of the curve | GMFI | No |
| 157 | 155 | 298.5 | 155.8 | 173 | 168 | 493.5 | | | 233 (Neg +65) | Median linear channel | No |
| 159 | 408 | 623 | 383 | 294 | 295 | 658 | | | 355 (60 mean linear channel shift) | Mean linear channel | No |
| 160 | 194.3 | 1338 | 130 | 75.3 | 36.9 | 517 | | | >78.1 (Neg +2SD) | Mean linear channel | No |
| 163 | 1.2 | 2.9 | 1.2 | 1 | 1 | 1.3 | | | 1.7 Geomean log channel | Geomean log channel | Yes |
| 164 | 79 | 162 | 8 | 47 | 23 | 469 | | | 69 (3x MFI neg control) | MFI | No |
| 167 | 49 | 422 | 61 | 32 | 21 | 1778 | | | 2SD | Median log channel | No |
| 169 | MLC 62.38 NR 93 | 59.91 89 | 46.17 69 | 39.69 60 | 7.06 | 1643.07 2462 | | | NR= (MFI serum/MFI neg control) x100 Positive= NR >200 B-cell SI≥0.30 | Mean log channel | No |
| 176 | SI.11 MESF 24.833 | 0.64 87.660 | 0 18.213 | 0.02 19.437 | 0 18.072 | 0.44 65.870 | | | | | No |
| 186 | 2.35 | 5.12 | 1.69 | 1.31 | 1.94 | 24.4 | | | Twice the local negative | MFI log channel | No |
| 190 | 159.5 | 927 | 142.5 | 82.7 | 68.1 | 755 | | | Ratio Samples/Negative >1.4 | Mean linear channel | No |
| 191 | MFI 23 12.4% | 90 28% | 121 10% | -25 7% | 315 >1% | | | | MFI >10 | | No |
| 193 | 194.51 | 910.93 | 213.43 | 125.78 | 87.36 | 738.49 | | | Negative control mean x2.5 | Geometric mean linear channel | No |
| 194 | 2.3 | 5.9 | 1.7 | 1 | 0.8 | 17 | | | Ratio >1.5 | MuIX | No |
| 195 | 886 | 5126 | 941 | 493 | 416 | 12144 | | | Test/Neg control >1.35 | Median log channel | Yes |
| 201 | 2.62 | 14.5 | 1.78 | 2.98 | 2.43 | 26.8 | | | x-mean ratio ≥2.5 | x-mean | No |
| 202 | 6 | 50 | 6 | 3 | 6 | 100 | | | 8% above the local negative control | Linear | No |
| 204 | 7.61 | 25.6 | 6.02 | 4.81 | 5.79 | 23.2 | | | 11.58 = 2x local neg control | Mean log channel | No |
| 209 | 3.37 | 17.73 | 3.38 | 1.43 | 615 | 2226 | | | >1.69 | Geomean log channel | Yes |
| 218 | 6564 | 17743 | 4598 | 2954 | 2734 | 7866 | | | 2734 x1.7 = 4647.8 | Geometric MFI | No |
| 220 | 11.48 | 27.49 | 12.45 | 12.66 | 11.29 | | 576.55 | 70.57 | 2SD | | No |
| 227 | | | | | | | | | | | |
| 235 | 4.75 | 14.7 | 2.78 | 2.03 | 1.67 | 25.7 | | | Median +2SD | Median log channel | No |
| 238 | 4780 | 26012 | 4342 | 2132 | 1699 | 23803 | | | MESF serum/MESF neg control | MESF | No |
| 245 | 20.8 | 100.8 | 15.8 | 2.8 | 50.7 | 84 | | | 20 linear channel shift | Linear channel shift | Yes |
| 246 | 93.8% | 89.7% | 90.6% | 21.1% | 8.1% | 97.6% | | | 30% | | No |
| 252 | 76.3 | 13.95 | 101.8 | 101.8 | 97.34 | 469.76 | | | xm median channel/neg median channel | Median channel ratio | No |
| 262 | Ratio 1.81 Lysis 17% | 7.59 88% | 1.6 12% | | 2439 | 134472 | | | Samples/Neg >2 Cell lysis >12% | Median channel log | No |
| 271 | 366 | 672 | 343 | 258 | 208 | 586 | | | 106 log channel shift | Median log channel | No |
| 283 | -19.19 | 501.05 | -103.23 | 37.08 | 276.32 | 367.25 | | | 140 channel shift | Channel shift | No |